TA169 Renal cell carcinoma - sunitinib: Review Update - January 2011

Decision to defer the review

The planned date for review of the above Technology Appraisal is February 2011. This is the date when NICE consults with relevant organisations on a review proposal to decide whether or not the guidance needs to be updated and, if so, how.

Since publication of TA169 in March 2009, NICE has also published Technology Appraisal no. 178 'Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma' with a planned review date of June 2011.

Given overlap between the two guidance publications, Guidance Executive has decided that the consideration to review TA169 will be deferred until June 2011 to coincide with the consideration of a review of TA178. In the meantime if you have any queries please contact Andrew Harding RPP Project Manager, (andrew.harding@nice.org.uk, 0161 870 3149).

January 2011

This page was last updated: 14 January 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.